Recent Publications and Media Highlights from CeBIL & Inter-CeBIL

In the past three months, the Center for Advanced Studies in Bioscience Innovation Law (CeBIL) and the International Collaborative Bioscience Innovation & Law (Inter-CeBIL) Programme have made significant contributions to the discourse on Bioscience innovation, intellectual property, and health law. From in-depth academic publications to insightful media commentary, these works continue to shape global understanding in these critical areas. Below is a roundup of the most notable publications and media features from CeBIL and Inter-CeBIL over the recent quarter.

• A call for responsible quantum technology by Urs Gasser, Eline De Jong & Mauritz Kop in Nature Physics.
• A Realist Perspective on AI Regulation by Viktor Mayer-Schönberger and Urs Gasser in foreignpolicy.com.
• Ændringer i EU’s lægemiddellovgivning vil belønne ikke berøve by Jakob Wested in Dagens Pharma.
• Analyzing antimicrobial resistance as a series of collective action problems by Isaac Weldon, Kathleen Liddell, Susan Rogers Van Katwyk, Steven J. Hoffman, Timo Minssen, Kevin Outterson, Stephanie Palmer, A. M. Viens, Jorge Viñuales in Policy Studies Journal.
• Decentralising the Self – Ethical Considerations in Utilizing Decentralised Web Technology for Direct Brain Interfaces by David M. Lyreskog, Hazem Zohny, Sebastian Porsdam Mann, Ilina Singh & Julian Savulescu in Science and Engineering Ethics.
• Det er ikke prisen det handler om by Jakob Wested in Dagens Pharma.
• Digital doppelgängers and lifespan extension: What matters? by Samuel Iglesias, Brian David Earp, Cristina Voinea, Sebastian Porsdam Mann, Anda Zahiu, Nancy Jecker, Julian Savulescu in American Journal of Bioethics.
• Drug Repurposing Via the Best Pharmaceuticals for Children Act by Ian T. T. Liu and Aaron S. Kesselheim in JAMA Pediatrics.
• Governing AI in the European Union: emerging infrastructures and regulatory ecosystems in health by Timo Minssen, Barry Solaiman, Lea Köttering, Jakob Wested, and Abeer Malik in Research Handbook on Health AI and the Law, Edward Elgar- Elgar Online.
• Governing AI With Intelligence by Urs Gasser in issues.org.
• How AI can enable cross-border data sharing in a fragmenting world by François Candelon, I. Glenn Cohen, Theodoros Evgeniou and Ke Rong in Fortune.com.
• Impact of Priority Review Voucher Eligibility on Research and Development of Medical Countermeasures by Stephanie Wang, Georg Hahn, Aaron S. Kesselheim in Clinical Pharmacology & Therapeutics.
• Liability for use of artificial intelligence in medicine by W. Nicholson Price II, Sara Gerke and I. Glenn Cohen in Research Handbook on Health AI and the Law, Edward Elgar- Elgar Online.
• Navigating the EU AI Act: Implications for Regulated Digital Medical Products by Mateo Aboy, Timo Minssen & Effy Vayena in Nature PJ Digital Medicine.
• New government drug repurposing programs: Opportunities and uncertainties by Johnathon Liddicoat, Ashleigh Hamidzadeh, Kathleen Liddell, Marco Schito, David Simon, Mateo Aboy and Timo Minssen in Science Translational Medicine.
• Research Handbook on Health AI and the Law edited by Barry Solaiman and I. Glenn Cohen in Health and Medical Law series, Edward Elgar- Elgar Online.
• Seeking a Better Paper Trail of Federal Research Funding by Liam Bendicksen, Aaron S. Kesselheim, William B. Feldman in JAMA.
• The EU AI Act: Implications for U.S. Health Care by Sebastian Porsdam Mann, I. Glenn Cohen and Timo Minssen in NEJM AI.
• The future of AI-powered therapy is here and mostly unregulated by I. Glenn Cohen in media piece by Grant Hill in Whyy.org.
• The Nature, Scope and Validity of Patent Pledges by Gabriela Lenarczyk, Timo Minssen, Mateo Aboy in Journal of Intellectual Property Law & Practice.
• The sufficiency of disclosure of medical artificial intelligence patents by Mateo Aboy, W. Nicholson Price II, Seth Raker & Kathleen Liddell in Nature Biotechnology.

Topics